About Flow Neuroscience
Flow Neuroscience develops brain stimulation headsets and therapy applications for the home treatment of major depressive disorder (MDD). Its headset uses transcranial direct current stimulation which is a pain-free technique and activates neural networks through gentle currents to reduce depression. The company was founded in 2016 and is based in Malmo, Sweden.
Flow Neuroscience's Product Videos
Flow Neuroscience's Products & Differentiators
Flow tDCS Headset
Small, wireless, and portable device that delivers transcranial direct current (tDCS). The headset is one of the first to provide a non-pharmacological and non-invasive way to target the physical causes of depression without side effects
Research containing Flow Neuroscience
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Flow Neuroscience in 1 CB Insights research brief, most recently on Aug 17, 2022.
Expert Collections containing Flow Neuroscience
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Flow Neuroscience is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Mental Health Tech
This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.
Flow Neuroscience Patents
Flow Neuroscience has filed 14 patents.
Neurotechnology, Electrotherapy, Neurophysiology, Implants (medicine), Neuroprosthetics
Neurotechnology, Electrotherapy, Neurophysiology, Implants (medicine), Neuroprosthetics
Latest Flow Neuroscience News
Jul 31, 2023
News provided by Share this article Results Show an Alternative Twice as Effective Compared to Antidepressant Medications LONDON, July 31, 2023 /PRNewswire/ -- Flow Neuroscience, the creators of the Flow tDCS headset that provides at-home non-invasive brain stimulation to treat depression, today announced the results of its FDA pivotal clinical trial. The trial results show that the Flow headset was twice as effective as the most commonly-prescribed antidepressants in the treatment of depression. * In July 2022, Flow received FDA Breakthrough Device Designation, demonstrating the innovative nature of the platform and the significant advantages it offers over existing approved or cleared alternatives. It was the first medical device in the category to achieve this status. Flow is now being reviewed for full FDA approval, which would make this device available as an at-home treatment option in the U.S. In a study of patients in the US and the UK, the largest-ever clinical trial of its kind, 56% of the participants using the Flow tDCS headset were relieved of all depressive symptoms within 10 weeks**. Daily use of Flow was confirmed to be safe with minimal side effects. Flow has already been granted regulatory approval in Europe where it is available over the counter via Flow's website and in major UK pharmacies. More than 12,000 people and 100 clinics/hospitals in Europe use Flow today, including NHS partnerships. Preliminary results include: The trial sites at the University of Texas and the University of East London measured the effectiveness and safety of the tDCS headset designed by Flow Neuroscience. 173 patients were taken through the at-home treatment program, completely remotely and with minimal supervision, over a 10-week period. This was the largest ever US/UK tDCS study for the treatment of depression. 56% of patients in the treatment group went into remission (complete relief from depression symptoms), and 62% had a clinical response (more than 50% improvement in depressive symptoms. )** The study showed that participants had greater than three times higher odds of getting substantially better if they got the active treatment vs if they got placebo/sham stimulation, approximately double the average effect size witnessed in the trials for the 21 best-selling antidepressants reviewed by the FDA. No major side effects were reported from the treatment group. Flow's study results come at a time when depression is at an all-time high among U.S. adults, but with nearly half of Americans in 2021 reporting they did not seek help for clinical-level mental health issues, citing an increased desire for self-help options. The Flow tDCS headset and treatment is conveniently administered at home five times a week, creating an effective, safe, and accessible treatment option for depression. How Flow works: The Flow headset uses a brain-stimulation technique called tDCS to target the left dorsolateral prefrontal cortex, which is the area of the brain associated with depression. Depression is associated with lowered activity in the Dorsolateral Prefrontal Cortex (DLPFC). This area of the brain helps regulate mood, and focus, and can even impact sleep and appetite. When this area of the brain has lower activity, these functions are affected. By delivering a weak electrical current (2 mA) to the DLPFC via electrodes placed on the forehead, activity increases in this part of the brain. This addresses what some researchers believe is one of the physical causes of depression. Since Flow can target specific brain areas involved in depression directly, users experience little to no side effects compared to antidepressants. Allan Young (Chair of Mood Disorders, Director of Centre for Affective Disorders in the Institute of Psychiatry, Psychology, and Neuroscience at King's College London) said: "These exciting and encouraging new data raise the prospect of a real advance in the treatment of depression. Major depression is undertreated throughout the world, and all of the currently widely used treatment modalities have significant limitations. The nature of this treatment, being both effective and well tolerated, means that it is a treatment which may be widely adopted and should be a helpful intervention for many people suffering from major depression." Azhar Zafar (GPA Director of Research, NHS GP, and Senior Lecturer at the University of Buckingham) said: "These findings are incredibly promising and align with the valuable insights gained from utilizing Flow in primary care. Flow has gained significant popularity among our NHS patients, and a considerable number of them willingly opt for Flow when presented with the choice for the treatment of depression with or without pharmacotherapy. This positive reception speaks volumes about the effectiveness and patient satisfaction associated with Flow." Flow Neuroscience co-founder Daniel Månsson said: "Depression is one of the most common mood disorders, and unfortunately, it is also one of the hardest to treat. Our core mission was to create a treatment that is effective and accessible to as many people as possible in their own homes, with little to no side effects. The results of this clinical trial show how effective this treatment has become and how breakthroughs are still possible in the treatment of depression." Corey Keller (Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University) said: 'These results show clear separation of active and sham treatment arms in a large, multisite, randomized controlled trial for at-home low-intensity brain stimulation for depression. Flow's novel brain stimulation approach could offer valuable opportunities for individuals to manage their depression from home effectively, signaling a very promising development in mental health treatment.' Visit www.flowneuroscience.com to find out more information about Flow's first at-home depression treatment. Key Stats about Flow Neuroscience: 12,000+ real-world users in UK and Europe Live in 100+ clinics and hospitals in UK and Europe 8 million minutes of stimulation using the Flow headset and over 260,000 stimulation sessions Flow attracts users from all ages and walks of life, with over one-third of users above 50 years of age More About Flow Neuroscience Founded in 2016, Flow Neuroscience's mission is to develop new ways to combat mental health issues with science and technology. The Flow headset is a medication-free treatment for depression, the leading cause of disability in the world. It combines a brain stimulation wearable and an app-based therapy program to create a new effective, safe, and affordable way to treat depression, at home. The Flow headset offers a treatment you can take with you from your home to your office to your everyday. On average, the majority of Flow headset users see significant improvements within 4 to 6 weeks of treatment. Notes to Editors: *Based on a comparison of odds ratios, a standardized way of comparing clinical trials and a form of measurement for the difference in effect between treatment and placebo. The study showed that participants had greater than three times higher odds of getting substantially better if they got the active treatment vs if they got placebo/sham stimulation, approximately double the average effect size witnessed in the trials for the 21 best-selling antidepressants reviewed by the FDA. **Measured by the Montgomery-Asberg Depression Rating Scale (MADRS). The trial was also measured by the Hamilton Depression Rating Scale (HDRS-17), and results demonstrated 45% clinical remission and 55% had an improvement of at least 50%.
Flow Neuroscience Frequently Asked Questions (FAQ)
When was Flow Neuroscience founded?
Flow Neuroscience was founded in 2016.
Where is Flow Neuroscience's headquarters?
Flow Neuroscience's headquarters is located at Sodra Tullgatan 3, Malmo.
What is Flow Neuroscience's latest funding round?
Flow Neuroscience's latest funding round is Incubator/Accelerator.
How much did Flow Neuroscience raise?
Flow Neuroscience raised a total of $11.9M.
Who are the investors of Flow Neuroscience?
Investors of Flow Neuroscience include MedTech Innovator, SOSV, HAX, Khosla Ventures, Zuhlke Ventures and 5 more.
Who are Flow Neuroscience's competitors?
Competitors of Flow Neuroscience include Sooma Medical and 3 more.
What products does Flow Neuroscience offer?
Flow Neuroscience's products include Flow tDCS Headset and 2 more.
Compare Flow Neuroscience to Competitors
Parasym is a neurotechnology company that operates in the healthcare sector, focusing on the development of innovative neuromodulation treatments. The company's main offerings include wearable devices that use bioelectrical signals to target neural circuits of organs, providing a non-invasive method of treatment that doesn't require drugs or surgery. Parasym primarily serves the healthcare industry, partnering with clinics and academic institutions for research and development. It was founded in 2015 and is based in London, England.
Neuroelectrics is a digital brain health company with a proprietary platform to diagnose and treat brain disorders, and improve overall brain health. The company develops products that quantify brain health and performance, predict neurodegenerative diseases, and treat neurological disorders with mild non-invasive neuromodulation.
Soterix Medical is a company that focuses on the development and deployment of innovative medical treatments, specifically in the field of neuropsychiatric and neurological disorders and rehabilitation. The company offers a range of products and services, including non-invasive neuromodulation devices, brain monitoring technology, and software for neurotargeting. These products are primarily used in clinical trials and human performance testing in the medical sector. It was founded in 2008 and is based in New York, New York.
BrainQ operates as a bioelectric medicine company. The company's main service is the development of precision neurology therapies using brain-computer interface technology, which are designed to target damaged neuronal networks and facilitate neurorecovery. Its therapies are primarily offered to the healthcare industry. It was founded in 2016 and is based in Jerusalem, Israel.
GrayMatters Health is a company focused on developing digital therapies for mental disorders, specifically within the healthcare and technology sectors. The company's main offering is a neuromodulation procedure that augments pharmacotherapy and psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). This procedure uses a proprietary technology to process EEG signals, helping patients regulate their symptoms under the supervision of a healthcare provider. It was founded in 2019 and is based in Haifa, Israel.
StimScience develops non-invasive personalized brain stimulation applications. Its first product Somnee is an electronic sleep aid headband using personalized non-invasive brain stimulation to significantly improve sleep health and quality. The company was founded in 2017 and is based in Berkeley, California.